HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s Mylanta, Mylicon Lines Return Via ‘Fixed-Term’ License With Infirst

This article was originally published in The Tan Sheet

Executive Summary

Unlike other OTC deals J&J made since McNeil Consumer Healthcare’s quality-control problems led to widespread recalls and a consent decree with FDA, the firm is not divesting the digestive health lines. Infirst will manufacture and market the products in the U.S. for an undisclosed period before the brands return to McNeil.

You may also be interested in...



J&J Includes Listerine In 20 Consumer Product Launches Planned In 2015

CEO Alex Gorsky says “20 key product launches” are planned for 2015, including extensions for the Listerine Healthy White mouthwash Neutrogena Hydro Boost skin care lines. Analgesics and upper respiratory products drive global OTC sales growth in the fourth quarter.

J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition

McNeil scaled up its manufacturing “volume and complexity substantially” following J&J’s acquisition of Pfizer’s consumer business in 2006, says McNeil Consumer VP Shane Freedman. “Just a few years later, we had the recalls” that led eventually to a consent decree with FDA,” he says.

J&J Prioritizes OTC Return With McNeil Remediation End In Sight

Johnson & Johnson CEO Alex Gorsky says bringing recalled OTCs such as Tylenol and Motrin products back to market is the firm’s “clear number one priority” in the near term. J&J also has a timetable for completing its responsibilities under a consent decree with FDA in place since 2011.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

RS123519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel